Company Encyclopedia
View More
name
Apellis Pharma
APLS.US
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops EMPAVELI to treat C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, hematopoietic stem cell transplantation-associated thrombotic microangiopathy, focal segmental glomerulosclerosis, and delayed graft function; and APL-3007, a small interfering RNA, or siRNA for the treatment of GA. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics Inc.
1.945 T
APLS.USMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
B
BiotechnologyIndustry
Industry Ranking27/394
Industry medianC
Industry averageD
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreB
    • ROE14.10%B
    • Profit Margin4.43%C
    • Gross Margin79.78%A
  • Growth ScoreA
    • Revenue YoY42.11%A
    • Net Profit YoY117.99%A
    • Total Assets YoY17.39%A
    • Net Assets YoY69.18%A
  • Cash ScoreA
    • Cash Flow Margin2259.36%A
    • OCF YoY42.11%A
  • Operating ScoreA
    • Turnover1.04A
  • Debt ScoreD
    • Gearing Ratio62.11%D

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Citi Reaffirms Their Buy Rating on Apellis Pharmaceuticals (APLS)

    Citi analyst Yigal Nochomovitz maintained a Buy rating on Apellis Pharmaceuticals, setting a price target of $117.80. The shares closed at $20.66. Nochomovitz, who covers the Healthcare sector, has an average return of 4.7% and a 39.51% success rate. Apellis has a Moderate Buy consensus with a price target of $38.27.

    Tip Ranks·
    US
    APLS
    +6.17%
    Tip Ranks·
    US
    APLS
    +6.17%

    Apellis Reports Positive Phase 3 Results for Its Kidney Disease Treatment Empaveli

    Apellis (APLS) announced positive Phase 3 results for its kidney disease treatment, Empaveli, published in the New England Journal of Medicine. The study showed a 68% reduction in proteinuria at Week 26, stabilization of kidney function, and reduced C3 staining. Results were consistent across adults and adolescents, including post-transplant patients. Empaveli is FDA-approved for patients 12 and older. Shares rose over 1% in after-hours trading.

    fidelity·
    US
    APLS
    +6.17%
    fidelity·
    US
    APLS
    +6.17%

    Apellis Wins FDA Approval for EMPAVELI in Rare Kidney Diseases

    Apellis Pharmaceuticals Inc. has received FDA approval for EMPAVELI® (pegcetacoplan) as the first treatment for C3 glomerulopathy and primary immune complex membranoproliferative glomerulonephritis in patients aged 12 and older. This approval follows positive results from the Phase 3 VALIANT study. In the EU, Apellis' partner Sobi® expects an opinion from the European Medicines Agency's CHMP by year-end.

    Reuters·
    US
    APLS
    +6.17%
    Reuters·
    US
    APLS
    +6.17%

    Geode Capital Management LLC Raises Stake in Apellis Pharmaceuticals, Inc. $APLS

    Geode Capital Management LLC increased its stake in Apellis Pharmaceuticals by 2.3% in Q2, owning 1.58% of the company. Analysts have mixed ratings, with a consensus "Hold" and a target price of $33.06. Apellis reported strong Q3 earnings, with revenue up 133% year-over-year. The stock opened at $21.59, with a market cap of $2.73 billion.

    Market Beat·
    US
    APLS
    +6.17%
    Market Beat·
    US
    APLS
    +6.17%

    Apellis Pharmaceuticals to Participate in Upcoming Investor Conferences

    Apellis Pharmaceuticals Inc. will participate in webcast fireside chats at Citi’s 2025 Global Healthcare Conference on December 2, 2025, and the Evercore 8th Annual Healthcare Conference on December 3, 2025. Live webcasts will be available on the Apellis website, with replays accessible for approximately 30 days following the events.

    Reuters·
    US
    APLS
    +6.17%
    Reuters·
    US
    APLS
    +6.17%
    © 2025 Longbridge｜Disclaimer